UC OSHA 300 log summary available

The record, which includes occupational injury and illness totals that occurred at UC in 2018, includes summaries available for the Uptown West and Medical campuses, UC Blue Ash and Clermont colleges

Contact: Jan Utrecht:  513-556-4968

The UC OSHA 300 Log Summary includes occupational injury and illness totals that occurred at UC in 2018. Summaries are available for the Uptown West and Medical campuses, UC Blue Ash, and Clermont Colleges.

Managers are required to share the university’s OSHA 300 Log Summary with employees.  The OSHA 300 Log summary of work-related injuries and illnesses is required by regulations to be posted annually from Feb. 1 through April 30.

This summary is a record of the calendar year 2018 occupational injury and illness totals that occurred at the University of Cincinnati.  Summaries are available for the Uptown West and Medical Campuses, UC Blue Ash College, and UC Clermont College.  Be sure to post the summary that represents your area in a conspicuous place or places where notices to your employees are customarily posted.

Access your summary from Enviornmental Health and Safety's web site at www.ehs.uc.edu.

Featured image: Professor Rashmi Jha and student Tommy engaging in some research in Clean Room at ERC. UC/Joseph Fuqua II

Related Stories

1

Engineers develop deft solution to orient robots in space

March 11, 2026

To keep a repair robot stable while fixing satellites in space, University of Cincinnati engineers took a page from experts in balance: bull riders. UC College of Engineering and Applied Science graduate student James Talavage and Professor Ou Ma looked at simple but effective ways for a robot to maintain orientation while working on a broken satellite in zero gravity.

2

Study: Additional radiation for liver cancer does not increase toxicity

March 10, 2026

New research led by University of Cincinnati Cancer Center researchers published in the American Journal of Clinical Oncology found external beam radiation therapy (EBRT) is safe to administer to patients with liver cancer even after they undergo a targeted internal radiation therapy called Y90.